Interplay between cardiovascular and thyroid dysfunctions: A review of clinical implications and management strategies.

Q3 Medicine
Endocrine regulations Pub Date : 2022-10-20 Print Date: 2022-10-01 DOI:10.2478/enr-2022-0033
Sanyal Debmalya, Ray Saumitra, Malhi Harshveer Singh
{"title":"Interplay between cardiovascular and thyroid dysfunctions: A review of clinical implications and management strategies.","authors":"Sanyal Debmalya,&nbsp;Ray Saumitra,&nbsp;Malhi Harshveer Singh","doi":"10.2478/enr-2022-0033","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular diseases (CVD) and thyroid dysfunction are two of the most prevailing disorders in the world that are closely interlinked. Actions of thyroid hormones are mediated via thyroid receptors present in the myocardium and the vascular tissue. Primary mechanism that links thyroid dysfunction with CVD is the modification of cardiovascular risk factors (dyslipidemia, blood pressure, coagulation parameters, etc.) resulting in endothelial and left ventricular systolic and diastolic dysfunction. Both overt and subclinical hyperthyroidism and hypothyroidism may cause adverse alterations in cardiac function. Hyperthyroidism gives rise to palpitation, atrial fibrillation, systolic hypertension, and heart failure, whereas hypothyroidism increases diastolic hypertension, pericardial effusion, and the risk of ischemic heart disease via altering lipid and coagulation parameters. Early recognition and treatment of thyroid dysfunction may prevent adverse cardiovascular events in patients with or without pre-existing CVD. Certain cardiac conditions and medications can cause alterations in thyroid function that may predispose an individual to higher morbidity and mortality. In certain situations, thyroid dysfunction treatment may have cardiovascular benefits. This study deals with the interplay between cardiovascular and thyroid dysfunctions associated with clinical implications and management strategies.</p>","PeriodicalId":11650,"journal":{"name":"Endocrine regulations","volume":"56 4","pages":"311-328"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine regulations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/enr-2022-0033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/1 0:00:00","PubModel":"Print","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Cardiovascular diseases (CVD) and thyroid dysfunction are two of the most prevailing disorders in the world that are closely interlinked. Actions of thyroid hormones are mediated via thyroid receptors present in the myocardium and the vascular tissue. Primary mechanism that links thyroid dysfunction with CVD is the modification of cardiovascular risk factors (dyslipidemia, blood pressure, coagulation parameters, etc.) resulting in endothelial and left ventricular systolic and diastolic dysfunction. Both overt and subclinical hyperthyroidism and hypothyroidism may cause adverse alterations in cardiac function. Hyperthyroidism gives rise to palpitation, atrial fibrillation, systolic hypertension, and heart failure, whereas hypothyroidism increases diastolic hypertension, pericardial effusion, and the risk of ischemic heart disease via altering lipid and coagulation parameters. Early recognition and treatment of thyroid dysfunction may prevent adverse cardiovascular events in patients with or without pre-existing CVD. Certain cardiac conditions and medications can cause alterations in thyroid function that may predispose an individual to higher morbidity and mortality. In certain situations, thyroid dysfunction treatment may have cardiovascular benefits. This study deals with the interplay between cardiovascular and thyroid dysfunctions associated with clinical implications and management strategies.

心血管和甲状腺功能障碍之间的相互作用:临床意义和管理策略的综述。
心血管疾病(CVD)和甲状腺功能障碍是世界上最常见的两种密切相关的疾病。甲状腺激素的作用是通过存在于心肌和血管组织中的甲状腺受体介导的。将甲状腺功能障碍与CVD联系起来的主要机制是心血管危险因素(血脂异常、血压、凝血参数等)的改变导致内皮和左心室收缩和舒张功能障碍。显性和亚临床甲状腺功能亢进和甲状腺功能减退均可引起心功能的不良改变。甲状腺功能亢进可引起心悸、心房颤动、收缩期高血压和心力衰竭,而甲状腺功能减退可通过改变血脂和凝血参数增加舒张期高血压、心包积液和缺血性心脏病的风险。早期识别和治疗甲状腺功能障碍可以预防有或无CVD患者的不良心血管事件。某些心脏疾病和药物可引起甲状腺功能的改变,这可能使个体易患更高的发病率和死亡率。在某些情况下,甲状腺功能障碍的治疗可能对心血管有益。本研究涉及心血管和甲状腺功能障碍之间的相互作用与临床意义和管理策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Endocrine regulations
Endocrine regulations Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
2.70
自引率
0.00%
发文量
33
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信